Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1739MR)

This product GTTS-WQ1739MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1739MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13314MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-06741086
GTTS-WQ10431MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ8572MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ15403MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ3050MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ13756MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ1458MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ5907MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW